JP6492106B2 - ３ｄ組織培養のための細胞の調製方法 - Google Patents
３ｄ組織培養のための細胞の調製方法 Download PDFInfo
- Publication number
- JP6492106B2 JP6492106B2 JP2016562830A JP2016562830A JP6492106B2 JP 6492106 B2 JP6492106 B2 JP 6492106B2 JP 2016562830 A JP2016562830 A JP 2016562830A JP 2016562830 A JP2016562830 A JP 2016562830A JP 6492106 B2 JP6492106 B2 JP 6492106B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- tissue culture
- culture
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 76
- 210000004027 cell Anatomy 0.000 claims description 179
- 210000003494 hepatocyte Anatomy 0.000 claims description 50
- 230000008569 process Effects 0.000 claims description 31
- 238000007747 plating Methods 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 13
- 238000003556 assay Methods 0.000 claims description 11
- 238000013456 study Methods 0.000 claims description 9
- 231100000419 toxicity Toxicity 0.000 claims description 9
- 230000001988 toxicity Effects 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 241000282465 Canis Species 0.000 claims description 7
- 239000000017 hydrogel Substances 0.000 claims description 7
- 231100000747 viability assay Toxicity 0.000 claims description 6
- 238000003026 viability measurement method Methods 0.000 claims description 6
- 230000001172 regenerating effect Effects 0.000 claims description 5
- 238000009511 drug repositioning Methods 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 231100000027 toxicology Toxicity 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 2
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 description 81
- 210000004185 liver Anatomy 0.000 description 29
- 230000035899 viability Effects 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 238000013459 approach Methods 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- 238000012604 3D cell culture Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 210000000130 stem cell Anatomy 0.000 description 10
- 230000003833 cell viability Effects 0.000 description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 206010019851 Hepatotoxicity Diseases 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 231100000304 hepatotoxicity Toxicity 0.000 description 6
- 230000007686 hepatotoxicity Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000010257 thawing Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000001338 self-assembly Methods 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 4
- 229960000497 trovafloxacin Drugs 0.000 description 4
- 238000012605 2D cell culture Methods 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 231100000334 hepatotoxic Toxicity 0.000 description 3
- 230000003082 hepatotoxic effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000009772 tissue formation Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010072268 Drug-induced liver injury Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000005499 meniscus Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002723 toxicity assay Methods 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- 238000013335 3D tissue model Methods 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 210000004703 blastocyst inner cell mass Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 230000034964 establishment of cell polarity Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003910 liver physiology Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000000441 neoplastic stem cell Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000002733 pharmacodynamic assay Methods 0.000 description 1
- 238000002732 pharmacokinetic assay Methods 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
- C12N5/0671—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5067—Liver cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1406716.9 | 2014-04-15 | ||
| GBGB1406716.9A GB201406716D0 (en) | 2014-04-15 | 2014-04-15 | Method of preparing cells for 3D tissue culture |
| PCT/EP2015/058174 WO2015158777A1 (en) | 2014-04-15 | 2015-04-15 | Method of preparing cells for 3d tissue culture |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511146A JP2017511146A (ja) | 2017-04-20 |
| JP2017511146A5 JP2017511146A5 (enExample) | 2018-11-15 |
| JP6492106B2 true JP6492106B2 (ja) | 2019-03-27 |
Family
ID=50844988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016562830A Active JP6492106B2 (ja) | 2014-04-15 | 2015-04-15 | ３ｄ組織培養のための細胞の調製方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20170037364A1 (enExample) |
| EP (1) | EP3132023B1 (enExample) |
| JP (1) | JP6492106B2 (enExample) |
| CN (1) | CN106459895B (enExample) |
| AU (1) | AU2015248875B9 (enExample) |
| CA (1) | CA2945548C (enExample) |
| DK (1) | DK3132023T3 (enExample) |
| GB (1) | GB201406716D0 (enExample) |
| SG (1) | SG11201608463WA (enExample) |
| WO (1) | WO2015158777A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6758026B2 (ja) * | 2015-04-17 | 2020-09-23 | 株式会社日立ハイテク | 成分分析装置、薬剤成分分析装置、成分分析方法及び薬剤成分分析方法 |
| WO2017117333A1 (en) * | 2015-12-30 | 2017-07-06 | Cellular Dynamics International, Inc. | Microtissue formation using stem cell-derived human hepatocytes |
| GB201609663D0 (en) | 2016-06-02 | 2016-07-20 | Stemtek Therapeutics Sl | Methods for producing cancer stem cell spheroids |
| US20210130790A1 (en) * | 2017-03-10 | 2021-05-06 | Merck Patent Gmbh | Infected Cell Cultures |
| CN109294971A (zh) * | 2018-09-29 | 2019-02-01 | 西安交通大学 | 一种用于药物筛选的颈动脉分叉三维细胞培养模型及其构建方法 |
| DE102019216886A1 (de) | 2019-10-31 | 2021-05-06 | Hahn-Schickard-Gesellschaft für angewandte Forschung e.V. | Transfer zumindest eines partikels in einer flüssigkeit von einer abgabeeinheit zu einer empfangseinheit |
| CN111471641B (zh) * | 2020-02-03 | 2021-11-05 | 东华大学 | 多片层单元水凝胶包被的仿生毛细血管网的3d打印制法 |
| CN111150885A (zh) * | 2020-03-05 | 2020-05-15 | 陕西佰傲干细胞再生医学有限公司 | 软骨微囊及其制备方法和应用 |
| US12076437B2 (en) | 2021-07-12 | 2024-09-03 | Brown University | Proangiogenic protein cocktails delivered in custom biomaterials to revascularize ischemic tissue |
| WO2025073379A1 (en) | 2023-10-06 | 2025-04-10 | Insphero Ag | Device for studying interactions of biological specimen |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2545100B1 (fr) * | 1983-04-29 | 1985-12-20 | Inst Nat Sante Rech Med | Procede d'obtention de cultures d'hepatocytes humains, les cultures obtenues et leurs applications biologiques et biochimiques |
| WO2003055487A1 (en) * | 2002-01-04 | 2003-07-10 | The University Of Adelaide | METHOD OF CONTROLLING DAMAGE MEDIATED BY α, β- UNSATURATED ALDEHYDES |
| WO2003084468A2 (en) * | 2002-04-03 | 2003-10-16 | Artecel Sciences, Inc. | Improvements of adipocytic differentiated adipose derived adult stem cells and uses thereof |
| JP2004254674A (ja) * | 2003-02-25 | 2004-09-16 | Mutsumi Takagi | 動物細胞の分化誘導培養方法 |
| WO2006032092A1 (en) * | 2004-09-24 | 2006-03-30 | Angioblast Systems, Inc. | Multipotential expanded mesenchymal precursor cell progeny (memp) and uses thereof |
| WO2007124023A2 (en) * | 2006-04-21 | 2007-11-01 | Wake Forest University Health Sciences | Ink-jet printing of tissues |
| CA2667359C (en) * | 2006-10-23 | 2014-07-22 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
| CA2677679A1 (en) * | 2007-02-12 | 2008-08-21 | Anthrogenesis Corporation | Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations |
| WO2010059828A1 (en) * | 2008-11-19 | 2010-05-27 | Anthrogenesis Corporation | Amnion derived adherent cells |
| US20110250688A1 (en) * | 2008-11-24 | 2011-10-13 | Immunotrex Corporation | Three Dimensional Tissue Generation |
| ES2609006T3 (es) * | 2009-10-16 | 2017-04-18 | Rutgers, The State University Of New Jersey | Procedimeinto de tratamiento de lesión crónica de tejido nervioso usando una estrategia de terapia celular |
| IL288647B2 (en) * | 2009-11-30 | 2023-12-01 | Pluri Biotech Ltd | Adherent Cells From Placenta And Use Of Same In Treating Heart Failure |
| US20110229970A1 (en) * | 2010-03-05 | 2011-09-22 | Florida State University Research Foundation | Dual-chamber perfusion bioreactor for orthopedic tissue interfaces and methods of use |
| EP2580319B1 (en) * | 2010-06-11 | 2016-07-20 | Takara Bio Europe AB | 3-dimensional scaffolds for improved differentiation of pluripotent stem cells to hepatocytes |
| CN103379921A (zh) * | 2010-12-17 | 2013-10-30 | 人类起源公司 | 使用羊膜来源的贴壁细胞治疗脊髓损伤和外伤性脑损伤 |
| AU2012308715A1 (en) * | 2011-09-12 | 2014-04-24 | Organovo, Inc. | Engineered tissues for in vitro research uses, arrays thereof, and methods of making the same |
-
2014
- 2014-04-15 GB GBGB1406716.9A patent/GB201406716D0/en not_active Ceased
-
2015
- 2015-04-15 CN CN201580020057.0A patent/CN106459895B/zh active Active
- 2015-04-15 US US15/303,455 patent/US20170037364A1/en not_active Abandoned
- 2015-04-15 SG SG11201608463WA patent/SG11201608463WA/en unknown
- 2015-04-15 AU AU2015248875A patent/AU2015248875B9/en not_active Ceased
- 2015-04-15 WO PCT/EP2015/058174 patent/WO2015158777A1/en not_active Ceased
- 2015-04-15 DK DK15723435.2T patent/DK3132023T3/da active
- 2015-04-15 JP JP2016562830A patent/JP6492106B2/ja active Active
- 2015-04-15 CA CA2945548A patent/CA2945548C/en active Active
- 2015-04-15 EP EP15723435.2A patent/EP3132023B1/en active Active
-
2023
- 2023-01-26 US US18/101,751 patent/US20230235277A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201608463WA (en) | 2016-11-29 |
| EP3132023A1 (en) | 2017-02-22 |
| CN106459895B (zh) | 2021-06-01 |
| CN106459895A (zh) | 2017-02-22 |
| US20170037364A1 (en) | 2017-02-09 |
| CA2945548C (en) | 2019-11-12 |
| AU2015248875A1 (en) | 2016-10-27 |
| JP2017511146A (ja) | 2017-04-20 |
| WO2015158777A1 (en) | 2015-10-22 |
| EP3132023B1 (en) | 2021-06-02 |
| AU2015248875B9 (en) | 2019-05-23 |
| GB201406716D0 (en) | 2014-05-28 |
| CA2945548A1 (en) | 2015-10-22 |
| AU2015248875B2 (en) | 2019-04-04 |
| US20230235277A1 (en) | 2023-07-27 |
| DK3132023T3 (da) | 2021-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6492106B2 (ja) | ３ｄ組織培養のための細胞の調製方法 | |
| JP2024150583A (ja) | 細胞ミクロコンパートメントおよびその調製方法 | |
| Mohr et al. | Accelerating cardiovascular research: recent advances in translational 2D and 3D heart models | |
| Hookway et al. | Aggregate formation and suspension culture of human pluripotent stem cells and differentiated progeny | |
| US8956867B2 (en) | Method for culturing stem cells | |
| US20080026460A1 (en) | Method for culturing stem cells | |
| Heidari Khoei et al. | Generating human blastoids modeling blastocyst-stage embryos and implantation | |
| CN104703698A (zh) | 细胞培养 | |
| CN111826338A (zh) | 一种快速培养肝芽类器官的方法 | |
| WO2022016165A2 (en) | Differentiation of trophectoderm lineage cells from pluripotent stem cells | |
| US11208629B2 (en) | Non-human primate induced pluripotent stem cell derived hepatocytes and uses thereof | |
| JP6950887B2 (ja) | 体外型の人工肝臓、及び体外型の人工肝臓用又は肝細胞培養用の器具 | |
| Hashizume et al. | Bovine trophoblast cell culture systems: a technique to culture bovine trophoblast cells without feeder cells | |
| Chen et al. | Expansion of human embryonic stem cells on cellulose microcarriers | |
| Fuegemann et al. | Differentiation of mouse embryonic stem cells into cardiomyocytes via the hanging‐drop and mass culture methods | |
| US20070148767A1 (en) | Method of forming multicellular spheroids from the cultured cells | |
| CN105695392B (zh) | 一种可提高肝细胞体外分化表型及功能的培养方法 | |
| Tao et al. | Enhancement and maintenance of hepatic metabolic functions by controlling 3D aggregation of cryopreserved human iPS cell-derived hepatocyte-like cells | |
| JP5758061B2 (ja) | 細胞クラスターの生成法 | |
| US20080280300A1 (en) | Method | |
| US20230392123A1 (en) | Spheroidal self-assembled peptide hydrogels comprising cells | |
| Raggi et al. | Generation of complex syngeneic liver organoids from induced pluripotent stem cells to model human liver pathophysiology | |
| Xu et al. | Perspective from the heart: The potential of human pluripotent stem cell‐derived cardiomyocytes | |
| TW201734206A (zh) | 高機能肝細胞及其利用 | |
| CN110381968A (zh) | 包含肝细胞的共培养物的组合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180404 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181002 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20181002 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20181012 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181023 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190116 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190205 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190304 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6492106 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |